ASCO 2017: Circulating tumour cells and survival in abiraterone and enzalutamide treated patients with castration-resistant prostate cancer

Chicago, IL ( Dr. De Laere presented a study investigating the prognostic value of circulating tumor cells (CTC) enumeration and dynamics in the context of second-line endocrine therapies (i.e. abiraterone or enzalutamide) in patients with metastatic castrate-resistant prostate cancer (mCRPC). 

This was a prospective multicenter study collecting blood samples from patients with mCRPC at baseline (n = 147) and follow-up (n = 95/147(64.6%)). At baseline, patients were stratified into favorable (< 5 CTCs/7.5mL) and unfavorable (≥5 CTCs/7.5mL) groups. Progression free survival (PFS) and overall survival (OS) were compared between groups. PSA changes at 10-12 weeks were also analyzed. 

Patients with ≥5 CTCs/7.5 mL (n = 59) at baseline had a PFS (3.9 vs. 11.3 months, p< 0.0001) and OS (9.34 months vs. not reached, p< 0.0001). Patients demonstrating increasing CTCs (n = 21) on therapy had a shorter PFS (4.03 vs. 10.36 vs. 13.08 months, p < 0.0001) and OS (11.2 months vs. not reached, p < 0.0001), compared to patients with decreasing (n = 41) and stable (n = 33) CTCs, respectively. Multivariable analysis showed that the number of CTCs (HR (95%CI): 1.0054 (1.0006–1.010), p= 0.0260) and an increasing follow-up CTC count (HR (95%CI): 2.8987 (1.2856–6.536), p= 0.0103) were independent predictors of PFS. CTC increase was the sole independent predictor for OS (HR 7.3512, 95% CI: 1.7953–30.101, p= 0.0055). At 10-12 weeks, a PSA response of ≥30% and ≥50% was achieved in 46/83 (55.4%) and 33/83 (39.8%) patients, respectively, which was statistically different between chemo-naive or pretreated patients (≥30%: p= 0.0395), patients with increasing, stable or decreasing CTC counts (≥30%: p= 0.0019; ≥50%: p= 0.0032), and patients with increasing or stable/decreasing CTC counts (≥30%: p= 0.0006; ≥50%: p= 0.0014). 

In summary, CTC levels are associated with PFS and OS in mCRPC patients, starting a new line of endocrine therapy. Follow-up CTC enumeration is associated with PSA response and its dynamics are an independent predictor of PFS and OS.

Presented By: Bram De Laere, MSc, Center for Oncological Research (CORE), University of Antwerp, Antwerp, Belgium

Written By: Hanan Goldberg, MD, Urologic Oncology Fellow (SUO), University of Toronto, Princess Margaret Cancer Centre, Toronto, Ontario, Canada
Twitter: @GoldbergHanan

at the 2017 ASCO Annual Meeting - June 2 - 6, 2017 - Chicago, Illinois, USA

Newsletter subscription

Free Daily and Weekly newsletters offered by content of interest

The fields of GU Oncology and Urology are rapidly advancing. Sign up today for articles, videos, conference highlights and abstracts from peer-review publications by disease and condition delivered to your inbox and read on the go.